CAJ | 학술논문

目的探讨莉芙敏联合帕罗西丁治疗围绝经期抑郁症的疗效和安全性.方法将围绝经期抑郁症患者120例数字随机分为治疗组和对照组,每组各60例,其中治疗组给予莉芙敏每次1片,2次/d,口服,和帕罗西丁20 mg,1次/d,口服；对照组仅给予帕罗西丁20 mg,1次/d,口服.连续服用2个月后,观察治疗前后各组汉密尔顿抑郁量表(HAMD)评分及考普曼(Kupperman)评分法评估疗效,并对比治疗前后血常规、尿常规、心电图、肝肾功和血压等,评定不良反应.结果通过HAMD评分比较,对于围绝经期抑郁症的改善,治疗组的总有效率为88.3％,对照组总有效率为78.3％,治疗组疗效显著高于对照组(P＜0.05)；治疗8周后,治疗组和对照组的KMI评分分别为(9.89±3.76)分和(15.75 ±5.84)分,两组比较,差异有统计学意义(P＜0.01)；联合用药明显优于单用帕罗西丁组.两组治疗前后血常规、尿常规、肝肾功、心电图和血压等无明显变化,差异无统计学意义(P＞0.05).结论莉芙敏联合帕罗西丁对围绝经期的抑郁程度有缓解作用,安全性高且不良发应少,患者易接受,值得临床进一步推广研究.
목적 탐토리부민연합파라서정치료위절경기억욱증적료효화안전성.방법 장위절경기억욱증환자120례수자수궤분위치료조화대조조,매조각60례,기중치료조급여리부민매차1편,2차/d,구복,화파라서정20 mg,1차/d,구복；대조조부급여파라서정20 mg,1차/d,구복.련속복용2개월후,관찰치료전후각조한밀이돈억욱량표(HAMD)평분급고보만(Kupperman)평분법평고료효,병대비치료전후혈상규、뇨상규、심전도、간신공화혈압등,평정불량반응.결과 통과HAMD평분비교,대우위절경기억욱증적개선,치료조적총유효솔위88.3％,대조조총유효솔위78.3％,치료조료효현저고우대조조(P＜0.05)；치료8주후,치료조화대조조적KMI평분분별위(9.89±3.76)분화(15.75 ±5.84)분,량조비교,차이유통계학의의(P＜0.01)；연합용약명현우우단용파라서정조.량조치료전후혈상규、뇨상규、간신공、심전도화혈압등무명현변화,차이무통계학의의(P＞0.05).결론 리부민연합파라서정대위절경기적억욱정도유완해작용,안전성고차불량발응소,환자역접수,치득림상진일보추엄연구.
Objective To explore the efficacies and safety of combined treatment of remifemin and paroxetine for perimenopausal depression.Methods A total of 120 patients with perimenopausal depression were digital randomly divided into the treatment and control groups (n =60 each).The treatment group received oral remifemin one tablet twice daily and paroxetine 20 mg once daily for 2 months while the control group oral paroxetine 20 mg once daily for 2 months.The Hamilton depression scale (HAMD) and Kupperman scale were used to assess the therapeutic efficacies.Blood and urine routine,electrocardiography,liver function,kidney function and blood pressure before and after treatment were examined to assess the side effects.Results For the improvement of perimenopausal depression on HAMD,the total effective rates of the treatment and control groups were 88.3％ and 78.3％ respectively.The therapeutic efficacy of the treatment group was significantly higher tban that of the control group(P ＜ 0.05).After 8-week treatment,Kupperman menopausal indices of the treatment and control groups were 9.89 ±3.76 and 15.75 ± 5.84 respectively.There was also significant difference (P ＜ 0.01).No significant changes existed in blood routine,urine routine,liver function,kidney function,blood pressure,ECG or blood pressure before and after treatment (P ＞ 0.05).Conclusion The combined treatment of remifemin and paroxetine for perimenopausal depression can improve the efficacies.It is easily accepted by patients for its higher safety and fewer side-effects.It is worthy of a wider application and further researches.